OUR PRODUCTS
Our Pipeline
We challenge ourselves to rethink the way medicines are developed,
and
are investing now to bring more value to patients in the future.
We strive for constant innovation and we are putting our passion and expertise to work in new areas including gastroenterology and endocrinology.
SB26
Novel biologic
- Molecule Ulinastatin-Fc
Fusion Protein - Therapeutic Area Gastroenterology
SB27
Biosimilar candidate
- Molecule Pembrolizumab
- Reference Biologic Keytrudai
- Therapeutic Area Oncology
*Pipeline last updated Feb 2025
- i
Keytruda is a registered trademark of Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada.
